1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1646
  6. Examiner Sang

Examiner Sang Hong

1646-SANG-HONG

Employment Information

Art Unit:1646 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
514 — Drug, bio-affecting and body treating compositions
506 — Combinatorial chemistry technology: method, library, apparatus
425 — Plastic article or earthenware shaping or treating: apparatus
Phone:(571) 272-8145
Email:hong.sang@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:21 years
Grade:GS-14

Grant Rate and Difficulty Ranking

76
3-Year Grant rate: 56% over 377 cases
Difficulty: Harder
Difficulty Percentile: 76th

With Examiner Sang, you have a 56% chance of getting an issued patent by 3 years after the first office action. Examiner Sang is a harder examiner and in the 76th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Sang, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1646

Examiner Sang's grant rate is higher than that of Art Unit 1646 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Sang 1.8
Art Unit 1646 1.5

Interview Benefit

Grant Rate without Interview

Examiner Sang has granted 166 of 311 cases without any applicant-requested interviews for a grant rate of 53%.

Grant Rate with Interview

Examiner Sang has granted 44 of 66 cases with at least one applicant-requested interview for a grant rate of 67%.

Interview Benefit

With Examiner Sang, conducting an interview increases your chance of getting a patent granted by 26%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17283915 Means And Methods For Detecting Soy Allergens Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18469458 Partitioning Systems And Methods For Determining Multiple Types Of Cancers Patented View
17712167 Compositions And Methods For Treatment And Prevention Of Alzheimer's Disease Patented View
17783182 Antibodies Having Specificity To Her4 And Uses Thereof Patented View
17790282 Methods Of Treating Clear Cell Renal Cell Carcinoma (Ccrcc) Using Axl Decoy Receptors Abandoned View
16651907 Novel Platforms For Co-Stimulation, Novel Car Designs And Other Enhancements For Adoptive Cellular Therapy Patented View
18644963 Hydrogel Particles As Feeder Cells And As Synthetic Antigen Presenting Cells Abandoned View
17818298 Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And Another Anti-Cancer Agent Abandoned View
17412572 Cells And Methods For Improved Immunotherapy Patented View
18702095 Cold Atmopsheric Plasma Treated Pan-Cancer Epitope Peptide Within The Collagen Type Vi A-3 (Col6a3) Protein As Cancer Vaccine Abandoned View
18317358 Ny-Eso-1-Containing Artificial Adjuvant Vector Cell For Use In Treatment Of Cancer Abandoned View
17421053 Multi-Functional Fusion Proteins And Uses Thereof Patented View
16627270 Compositions And Methods For Adoptive Cell Therapy Patented View
18343126 Therapeutic Molecules Abandoned View
17780932 Separated Antigen Axl Binding Protein And Use Thereof Abandoned View
17686920 Antibodies Directed To Her-3 And Uses Thereof Abandoned View
18307638 Anti-Erbb3 Antibodies Patented View
18179159 Anti-L1-Cam Antibodies And Uses Thereof Patented View
18285649 Compositions And Methods For The Prevention Or Treatment Of Rheumatoid Arthritis Patented View
17818151 Marker For Pancreatic Cancer And Intraductal Papillary Mucinous Neoplasms Patented View
17276882 Use Of Antagonists Of Th17 Cytokines For The Treatment Of Bronchial Remodeling In Patients Suffering From Allergic Asthma Patented View
18167318 Single Domain Antibodies To Programmed Cell Death Protein 1 (Pd-1) Abandoned View
17271841 Biomarkers, Compositions, And Methods For Diagnosing And Treating Subjects Exposed To Protein/heparin Complexes Abandoned View
15439386 Actrii Antagonists For Use In Increasing Immune Activity Abandoned View
18062619 Matrix Metalloprotease-Cleavable And Serine Protease-Cleavable Substrates And Methods Of Use Thereof Patented View
17285861 Use Of Anti-Fam19a5 Antibodies Patented View
17813274 Recombinant Microorganisms As A Versatile And Stable Platform For Production Of Antigen-Binding Molecules Abandoned View
17591109 Anti-C5a Antibodies And Uses Thereof Abandoned View
17812848 Transgene Genetic Tags And Methods Of Use Patented View
17283786 Binding Proteins Specific For Ha-1h And Uses Thereof Patented View
17430938 T Cell Receptors Specific To B-Cell Maturation Antigen For Treatment Of Cancer Patented View
17715875 Anti-Pd-1 Antibody In Combination With An Anti-Cd30 Antibody In Cancer Treatment Abandoned View
18514019 Cancer Cytotoxic Exosome Formulations And Methods For Use In Treating Cancer Patented View
18704212 Molecular Marker For Determining Very-Early-Stage Onset Risk Of Gastric Cancer And Evaluating Progression Risk Of Pre-Cancerous Lesion Of Gastric Cancer, And Use Thereof In Diagnostic Kit Abandoned View
16994953 Psma And Cd3 Bispecific T Cell Engaging Antibody Constructs Patented View
18295645 Recombinant Polyclonal Proteins Targeting Covid-19 And Methods Of Use Thereof Patented View
18054346 Cell Compositions And Methods For Cancer Therapy Abandoned View
17616755 Purified Double Negative T Cell And Preparation And Use Thereof Patented View
17958401 Combination Therapy For A Stable And Long Term Engraftment Abandoned View
17291159 Ido Activity As A Marker Of Tumor Immune Escape And Ido Inhibitors As A Means Of Enhancing T Cells Response To Antigen Specific Vaccine Abandoned View
18102922 Combination Of The Application Of Antibodies For Immunostimulation Together With Glucocorticoids Abandoned View
17949016 Method Of Deriving A Value For Percent Biomarker Positivity For Selected Cells Present In A Field Of View Abandoned View
17459905 B1sp Fusion Protein Therapeutics, Methods, And Uses Patented View
17361477 Use Of Leukemia-Derived Cells In Ovarian Cancer Vaccines Patented View
18424381 Method And Composition For Inducing Tolerance Abandoned View
18323013 Dual Conjugation Process For Preparing Antibody-Drug Conjugates Patented View
17606847 Anti-Human Ephrin B1 Antibodies And Uses Thereof Abandoned View
17284188 Treatment With Highly Siaylated Igg Compositions Abandoned View
17933088 High Avidity Antigen Recognizing Constructs Patented View
17282325 Leucine-Rich Alpha2 Glycoprotein Composition Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.